Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price reached a new 52-week high on Monday . The company traded as high as $50.20 and last traded at $49.23, with a volume of 352535 shares traded. The stock had previously closed at $47.17.
Gemini Therapeutics Trading Down 2.7 %
The company has a market capitalization of $2.08 billion, a PE ratio of -47.92 and a beta of -0.12. The stock’s 50-day moving average is $39.41 and its two-hundred day moving average is $49.04.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Using the MarketBeat Stock Split Calculator
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- What is the Shanghai Stock Exchange Composite Index?
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
